Category: 1214362-62-5

On May 13, 2004, Bit, Rino Antonio; Giblin, Gerard Martin Paul; Hall, Adrian; Hurst, David Nigel; Kilford, Ian Reginald; Miller, Neil Derek; Scoccitti, Tiziana published a patent.Application In Synthesis of Ethyl 2-bromo-6-fluorobenzoate The title of the patent was Preparation of benzoic acids and related compounds as EP1 receptor antagonists for the treatment of prostaglandin mediated diseases.. And the patent contained the following:

Title compounds I [A = (un)substituted aryl, 5 or 6-membered heterocyclyl ring, bicyclic heterocyclyl; B = Ph, pyridyl; Z = O, S, SO, etc.; R1 = CO2R4, CN, CONR5R6, etc.; R2a, R2b = H, halogen, (un)substituted alkyl, etc.; Rx = (un)substituted alkyl, CQaQb-heterocyclyl, CQaQb-bicyclic heterocyclyl, etc.; R4, R5 = H, (un)substituted alkyl; R6 = H, (un)substituted alkyl, heteroaryl, etc.; R8, R9 = H, Cl, F, etc.; Qa, Qb = H, CH3] and their pharmaceutically acceptable derivatives were prepared For example, the Suzuki coupling of Et 2′-bromobiphenyl-3-carboxylate and 2-benzyloxy-5-chlorophenylboronic acid, e.g., prepared from 3-ethoxycarbonylphenylboronic acid, followed by hydrolysis afforded compound I [A-R1 = 3-carboxyphenyl; Z = O; R2a = H, R2b = 5-Cl; R8, R9 = H] in 39% overall yield. In human prostanoid EP1 receptor binding assays, 90-examples of compounds I exhibited pIC50 values ranging from 6.0->9.0 at the EP1 receptor and pIC50 values of <6.0 at the EP3 receptor. Of note, no toxicol. effects are indicated/expected (sic) when the compounds I are administered at the assay concentration of 3 nM. Compounds I are claimed useful for the treatment of prostaglandin mediated diseases, e.g., inflammation, pain, etc. The experimental process involved the reaction of Ethyl 2-bromo-6-fluorobenzoate(cas: 1214362-62-5).Application In Synthesis of Ethyl 2-bromo-6-fluorobenzoate

The Article related to benzoic acid derivative preparation ep1 receptor antagonist prostaglandin disease, antiinflammatory agent benzoic acid derivative preparation ep1 receptor antagonist, analgesic benzoic acid derivative preparation ep1 receptor antagonist and other aspects.Application In Synthesis of Ethyl 2-bromo-6-fluorobenzoate

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On January 3, 2013, Geneste, Herve; Ochse, Michael; Drescher, Karla; Behl, Berthold; Laplanche, Loic; Dinges, Juergen; Jakob, Clarissa published a patent.Product Details of 1214362-62-5 The title of the patent was Preparation of isoindole carboxamides, pyrrolopyridine carboxamides, and similar compounds as inhibitors of phosphodiesterase type 10A for treating neurological and psychiatric disorders. And the patent contained the following:

The present invention relates to novel carboxamide compounds of general formula I (wherein X1-X4 are N or (un)substituted CH, with provisos; A is O, S, SO, SO2, substituted N, or (un)substituted CH2; Het is monocyclic hetaryl, fused bicyclic hetaryl, or Ph, all of which may be substituted; and R7-R10 are independently H, halo, C1-4 alkyl, etc.), pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties as inhibitors of phosphodiesterase type 10A and are particularly suitable for treating or controlling medical disorders selected from neurol. disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders. Synthetic procedures for preparing I are exemplified. Example compound II was prepared in a 5-step synthesis that culminated in reaction of 4-methyl-[2,4′]bipyridinyl-3-carboxylic acid Me ester and 2-quinolin-2-ylethylamine. In a PDE10A inhibition assay, II had an IC50 <100 nM. The experimental process involved the reaction of Ethyl 2-bromo-6-fluorobenzoate(cas: 1214362-62-5).Product Details of 1214362-62-5

The Article related to isoindole pyrrolopyridine carboxamide preparation inhibitor pde10a neurol psychiatric disorder, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Product Details of 1214362-62-5

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On May 13, 2004, Bit, Rino Antonio; Giblin, Gerard Martin Paul; Hall, Adrian; Hurst, David Nigel; Kilford, Ian Reginald; Miller, Neil Derek; Scoccitti, Tiziana published a patent.Application In Synthesis of Ethyl 2-bromo-6-fluorobenzoate The title of the patent was Preparation of benzoic acids and related compounds as EP1 receptor antagonists for the treatment of prostaglandin mediated diseases.. And the patent contained the following:

Title compounds I [A = (un)substituted aryl, 5 or 6-membered heterocyclyl ring, bicyclic heterocyclyl; B = Ph, pyridyl; Z = O, S, SO, etc.; R1 = CO2R4, CN, CONR5R6, etc.; R2a, R2b = H, halogen, (un)substituted alkyl, etc.; Rx = (un)substituted alkyl, CQaQb-heterocyclyl, CQaQb-bicyclic heterocyclyl, etc.; R4, R5 = H, (un)substituted alkyl; R6 = H, (un)substituted alkyl, heteroaryl, etc.; R8, R9 = H, Cl, F, etc.; Qa, Qb = H, CH3] and their pharmaceutically acceptable derivatives were prepared For example, the Suzuki coupling of Et 2′-bromobiphenyl-3-carboxylate and 2-benzyloxy-5-chlorophenylboronic acid, e.g., prepared from 3-ethoxycarbonylphenylboronic acid, followed by hydrolysis afforded compound I [A-R1 = 3-carboxyphenyl; Z = O; R2a = H, R2b = 5-Cl; R8, R9 = H] in 39% overall yield. In human prostanoid EP1 receptor binding assays, 90-examples of compounds I exhibited pIC50 values ranging from 6.0->9.0 at the EP1 receptor and pIC50 values of <6.0 at the EP3 receptor. Of note, no toxicol. effects are indicated/expected (sic) when the compounds I are administered at the assay concentration of 3 nM. Compounds I are claimed useful for the treatment of prostaglandin mediated diseases, e.g., inflammation, pain, etc. The experimental process involved the reaction of Ethyl 2-bromo-6-fluorobenzoate(cas: 1214362-62-5).Application In Synthesis of Ethyl 2-bromo-6-fluorobenzoate

The Article related to benzoic acid derivative preparation ep1 receptor antagonist prostaglandin disease, antiinflammatory agent benzoic acid derivative preparation ep1 receptor antagonist, analgesic benzoic acid derivative preparation ep1 receptor antagonist and other aspects.Application In Synthesis of Ethyl 2-bromo-6-fluorobenzoate

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary